Geron Corporation (NASDAQ: GERN) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Geron Corporation to related companies based on the strength of its valuation, dividends, analyst recommendations, risk, earnings, institutional ownership and profitability.

Insider & Institutional Ownership

38.8% of Geron Corporation shares are held by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 7.1% of Geron Corporation shares are held by company insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Geron Corporation and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron Corporation 0 2 2 0 2.50
Geron Corporation Competitors 753 3008 11116 225 2.72

Geron Corporation presently has a consensus price target of $4.17, indicating a potential upside of 99.36%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.67%. Given Geron Corporation’s higher probable upside, research analysts clearly believe Geron Corporation is more favorable than its peers.

Volatility and Risk

Geron Corporation has a beta of 2.76, meaning that its stock price is 176% more volatile than the S&P 500. Comparatively, Geron Corporation’s peers have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.

Profitability

This table compares Geron Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Geron Corporation -433.72% -21.30% -19.74%
Geron Corporation Competitors -5,536.49% -454.28% -42.57%

Valuation & Earnings

This table compares Geron Corporation and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Geron Corporation $5.91 million -$26.81 million -13.06
Geron Corporation Competitors $261.64 million $67.77 million -7.02

Geron Corporation’s peers have higher revenue and earnings than Geron Corporation. Geron Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Geron Corporation peers beat Geron Corporation on 8 of the 12 factors compared.

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.